Published in Ann Surg on August 01, 2004
An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat (2007) 2.65
Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev (2007) 1.76
First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer (2006) 1.53
Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology (2009) 1.48
Lymphangiogenesis and cancer metastasis. J Cell Mol Med (2009) 1.47
Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer (2006) 1.30
Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis. Hum Pathol (2008) 1.19
Lymphangiogenesis and cancer. Genes Cancer (2011) 1.16
Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer (2006) 1.15
Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer. BMC Cancer (2008) 1.05
Cancer invasion and metastasis: interacting ecosystems. Virchows Arch (2009) 1.05
A potent, imaging adenoviral vector driven by the cancer-selective mucin-1 promoter that targets breast cancer metastasis. Clin Cancer Res (2009) 1.02
Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients. World J Surg (2007) 1.00
Tumor lymphangiogenesis as a potential therapeutic target. J Oncol (2012) 0.97
Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance. J Cancer Res Clin Oncol (2007) 0.97
Importance of lymph vessels in gastric cancer: a prognostic indicator in general and a predictor for lymph node metastasis in early stage cancer. J Clin Pathol (2006) 0.95
A quantitative analysis of lymphatic vessels in human breast cancer, based on LYVE-1 immunoreactivity. Br J Cancer (2005) 0.91
Lymph vascular invasion in invasive mammary carcinomas identified by the endothelial lymphatic marker D2-40 is associated with other indicators of poor prognosis. BMC Cancer (2008) 0.89
Benefits and adverse effects of endocrine therapy. Ann Oncol (2010) 0.88
Increased density and diameter of lymphatic microvessels correlate with lymph node metastasis in early stage invasive colorectal carcinoma. Virchows Arch (2006) 0.88
Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis. Clin Exp Metastasis (2013) 0.87
Role of lymphangiogenesis in epithelial ovarian cancer. Br J Cancer (2006) 0.86
Radiotherapy can improve the disease-free survival rate in triple-negative breast cancer patients with T1-T2 disease and one to three positive lymph nodes after mastectomy. Oncologist (2013) 0.86
Factors influencing the outcome of breast cancer patients with 10 or more metastasized axillary lymph nodes. Int J Clin Oncol (2011) 0.85
The prognostic significance of determining DNA content in breast cancer by DNA image cytometry: the role of high grade aneuploidy in node negative breast cancer. J Clin Pathol (2007) 0.84
Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer. BMC Cancer (2014) 0.82
Lymphangiogenesis and lymph node metastasis in breast cancer. Mol Cancer (2008) 0.81
Tumor characteristics influencing non-sentinel lymph node involvement in clinically node negative patients with breast cancer. J Breast Cancer (2011) 0.81
Clinical significance of lymph vessel density in T3 colorectal carcinoma. Int J Colorectal Dis (2012) 0.81
Locoregional therapy in luminal-like and HER2-enriched patients with de novo stage IV breast cancer. Springerplus (2013) 0.80
Overexpression of both platelet-derived growth factor-BB and vascular endothelial growth factor-C and its association with lymphangiogenesis in primary human non-small cell lung cancer. Diagn Pathol (2014) 0.80
Breast Cancer Subtype is Associated With Axillary Lymph Node Metastasis: A Retrospective Cohort Study. Medicine (Baltimore) (2015) 0.79
Correlation of lymphovascular invasion with clinicopathological factors in invasive breast cancer: a meta-analysis. Int J Clin Exp Med (2015) 0.79
Inhibition of breast cancer growth and metastasis by a biomimetic peptide. Sci Rep (2014) 0.79
The clinicopathological significance of angiogenesis in hindgut neuroendocrine tumors obtained via an endoscopic procedure. Diagn Pathol (2016) 0.78
Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls. BMC Cancer (2010) 0.78
Differential prognostic indicators for locoregional recurrence, distant recurrence, and death of breast cancer. ISRN Oncol (2013) 0.78
Thrombocytes Correlate with Lymphangiogenesis in Human Esophageal Cancer and Mediate Growth of Lymphatic Endothelial Cells In Vitro. PLoS One (2013) 0.78
Clinicopathological significance of lymphangiogenesis detected by immunohistochemistry using D2-40 monoclonal antibody in breast cancer. Fukushima J Med Sci (2016) 0.78
Lymphatic vascular density and lymphangiogenesis during tumour progression of carcinoma ex pleomorphic adenoma. J Clin Pathol (2006) 0.77
Lithium inhibits tumor lymphangiogenesis and metastasis through the inhibition of TGFBIp expression in cancer cells. Sci Rep (2016) 0.77
Blood vessel invasion and other variables as predictors of long-term survival in Japanese and British patients with primary invasive breast cancer. Int J Clin Exp Pathol (2014) 0.77
Histological vascular invasion is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Oncol Lett (2016) 0.77
Incomplete inside-out growth pattern in invasive breast carcinoma: association with lymph vessel invasion and recurrence-free survival. Virchows Arch (2011) 0.77
Expression of podoplanin in the invasion front of oral squamous cell carcinoma is not prognostic for survival. Virchows Arch (2015) 0.77
Different types of tumor vessels in breast cancer: morphology and clinical value. Springerplus (2015) 0.76
Prognostic and Predictive Markers for Treatment Decisions in Early Breast Cancer. Breast Care (Basel) (2011) 0.76
Immunostaining with D2-40 improves evaluation of lymphovascular invasion, but may not predict sentinel lymph node status in early breast cancer. BMC Cancer (2009) 0.76
Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3. Cell Rep (2016) 0.76
Tumor characteristics and therapy of elderly patients with breast cancer. J Cancer Res Clin Oncol (2016) 0.76
Lymphatic invasion and angiotropism in primary cutaneous melanoma. Lab Invest (2016) 0.75
Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat (2016) 0.75
High lymphatic vessel density and presence of lymphovascular invasion both predict poor prognosis in breast cancer. BMC Cancer (2017) 0.75
The relationship of lymphatic vessel density, lymphovascular invasion, and lymph node metastasis in breast cancer: a systematic review and meta-analysis. Oncotarget (2016) 0.75
Deciphering Pro-Lymphangiogenic Programs during Mammary Involution and Postpartum Breast Cancer. Front Oncol (2016) 0.75
Prognostic role of lymphatic vessel density and lymphovascular invasion in chemotherapy-naive and chemotherapy-treated patients with invasive breast cancer. Am J Transl Res (2017) 0.75
Relationship of Podoplanin and Glutathione S-transferases T1 Expression with Laryngeal Cancer. Int J Mol Cell Med (2012) 0.75
Lymphovascular invasion and histologic grade are associated with specific genomic profiles in invasive carcinomas of the breast. Tumour Biol (2014) 0.75
The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics. Int J Endocrinol (2016) 0.75
Biological and molecular aspects of lymph node metastasis in gastro-intestinal cancer. Int J Clin Oncol (2013) 0.75
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med (1991) 19.46
Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst (1992) 8.69
Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A (1995) 7.11
Lymphatic metastasis in the absence of functional intratumor lymphatics. Science (2002) 5.32
PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science (1990) 5.28
Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol (1999) 5.02
Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer (1983) 3.94
Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat (1995) 3.88
Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J Exp Med (2001) 3.74
Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell (2002) 3.11
Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res (2000) 2.64
Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst (2001) 2.64
Endothelial cell membranes contain podocalyxin--the major sialoprotein of visceral glomerular epithelial cells. J Cell Biol (1986) 2.25
Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer (1999) 1.97
Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol (2000) 1.93
Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol (1998) 1.66
Method for grading breast cancer. J Clin Pathol (1993) 1.46
Tumor-related prognostic factors for breast cancer. CA Cancer J Clin (1997) 1.43
Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res (2001) 1.40
Markers for the lymphatic endothelium: in search of the holy grail? Microsc Res Tech (2001) 1.39
Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions. Pathol Int (1998) 1.30
[Podoplanin--a specific marker for lymphatic endothelium expressed in angiosarcoma]. Verh Dtsch Ges Pathol (1999) 1.27
Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg (1999) 1.11
Traditional and newer pathologic factors. J Natl Cancer Inst Monogr (2001) 1.09
Identification of women with T1-T2 breast cancer at low risk of positive axillary nodes. J Surg Oncol (1997) 1.08
Lymphatic vessels and lymphangiogenesis in female cancer: mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies (Review). Oncol Rep (2002) 1.07
Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study Group. Ann Surg (2003) 1.06
Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer. Am J Surg (2002) 1.03
Inflammatory stromal reaction correlates with lymphatic microvessel density in early-stage cervival cancer. Anticancer Res (2002) 1.01
Simultaneous and sequential determinations of steroid hormone receptors in human breast cancer. Influence of intervening therapy. Ann Surg (1985) 0.94
Prognostic relevance of the endothelial marker CD 34 in ovarian cancer. Anticancer Res (1999) 0.93
Clinicopathologic study associated with long-term survival in Japanese patients with node-negative breast cancer. Br J Cancer (2000) 0.90
Identification of lymph and blood capillaries by immunohistochemical staining for various basement membrane components. Histochemistry (1991) 0.87
Frequency of first metastatic events in breast cancer: implications for sequencing of systemic and local-regional treatment. J Clin Oncol (1999) 0.87
Microvessels that predict axillary lymph node metastases in patients with breast cancer. Arch Surg (2000) 0.85
Prognosis of breast-carcinoma lymphagenesis evaluated by immunohistochemical investigation of vascular-endothelial-growth-factor receptor 3. Int J Cancer (2000) 0.84
Prognostic factors in breast cancer: a brief review. Anticancer Res (1998) 0.84
Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer. J Clin Oncol (1999) 0.82
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med (2009) 13.74
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol (2009) 6.51
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol (2011) 5.63
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (2015) 4.58
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol (2009) 4.12
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res (2011) 2.79
Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res (2002) 2.57
Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys (2007) 2.54
Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res (2013) 2.50
Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res (2004) 2.36
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst (2007) 2.34
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol (2008) 2.28
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst (2008) 1.95
Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol (2007) 1.90
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol (2009) 1.90
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther (2013) 1.90
Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest (2011) 1.88
A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer (2003) 1.88
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn (2009) 1.72
Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst (2012) 1.69
Breast cancer issues in developing countries: an overview of the Breast Health Global Initiative. World J Surg (2008) 1.67
Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer - a retrospective analysis. Radiother Oncol (2006) 1.63
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Clin Cancer Res (2008) 1.57
Differential gene expression profile in breast cancer-derived stromal fibroblasts. Breast Cancer Res Treat (2007) 1.54
Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist (2013) 1.54
Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. Int J Cancer (2003) 1.50
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat (2010) 1.50
Current value of intraoperative sonography during surgery for hepatic neoplasms. World J Surg (2002) 1.48
Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol (2004) 1.47
Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. Wien Klin Wochenschr (2004) 1.45
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol (2006) 1.44
Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat (2008) 1.42
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol (2007) 1.42
Long-term results of dose density therapy in patients with aggressive lymphoma. Ann Hematol (2004) 1.40
Assessment of gene transcription demonstrates connection with the clinical course of idiopathic interstitial pneumonia. Respiration (2008) 1.40
Preparing for prospective clinical trials: a national initiative of an excellence registry for consecutive pancreatic cancer resections. World J Surg (2014) 1.39
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch (2012) 1.37
Brca1 regulates in vitro differentiation of mammary epithelial cells. Oncogene (2002) 1.35
Comparison of two methods for enumerating circulating tumor cells in carcinoma patients. Cytometry B Clin Cytom (2005) 1.35
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer (2009) 1.33
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res (2012) 1.33
Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin Cancer Res (2003) 1.32
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol (2012) 1.32
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol (2011) 1.31
Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res (2003) 1.30
Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res Treat (2003) 1.29